Is MGX or MRNA more profitable?

Moderna has a net margin of -141.43% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -28.30% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -63.65% -44.52% Moderna -141.43% -28.30% -19.39%

Does the media prefer MGX or MRNA?

In the previous week, Moderna had 39 more articles in the media than Metagenomi. MarketBeat recorded 41 mentions for Moderna and 2 mentions for Metagenomi. Moderna's average media sentiment score of 0.19 beat Metagenomi's score of 0.00 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 7 Very Positive mention(s) 14 Positive mention(s) 10 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, MGX or PEPG?

Metagenomi has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Metagenomi $25.21M 1.53 -$87.87M -$2.49 N/A PepGen N/A N/A -$89.65M -$1.31 N/A

Is MGX or PEPG more profitable?

PepGen has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. PepGen's return on equity of -51.01% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -63.65% -44.52% PepGen N/A -51.01% -43.49%

Does the media prefer MGX or DTIL?

In the previous week, Precision BioSciences had 5 more articles in the media than Metagenomi. MarketBeat recorded 7 mentions for Precision BioSciences and 2 mentions for Metagenomi. Precision BioSciences' average media sentiment score of 0.85 beat Metagenomi's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precision BioSciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MGX or LUCD?

In the previous week, Metagenomi had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 2 mentions for Metagenomi and 1 mentions for Lucid Diagnostics. Metagenomi's average media sentiment score of 0.00 equaled Lucid Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Metagenomi (MGX) Competitors

$1.02 -0.09 (-7.69%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.08 +0.06 (+6.27%)

As of 10/2/2026 08:00 PM Eastern

Compare

MGX vs. MRNA, PEPG, DTIL, ABOS, and LUCD

Should you buy Metagenomi stock or one of its competitors? Metagenomi's main competitors and comparable companies include Moderna (MRNA), PepGen (PEPG), Precision BioSciences (DTIL), Acumen Pharmaceuticals (ABOS), and Lucid Diagnostics (LUCD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Metagenomi compare to Moderna?

Metagenomi (NASDAQ:MGX) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Metagenomi has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Moderna has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

In the previous week, Moderna had 39 more articles in the media than Metagenomi. MarketBeat recorded 41 mentions for Moderna and 2 mentions for Metagenomi. Moderna's average media sentiment score of 0.19 beat Metagenomi's score of 0.00 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	7 Very Positive mention(s)	14 Positive mention(s)	10 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral

Metagenomi has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.53	-$87.87M	-$2.49	N/A
Moderna	$1.94B	39.02	-$2.82B	-$7.99	N/A

Moderna has a net margin of -141.43% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -28.30% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
Moderna	-141.43%	-28.30%	-19.39%

Metagenomi presently has a consensus target price of $6.00, suggesting a potential upside of 488.24%. Moderna has a consensus target price of $77.83, suggesting a potential downside of 59.04%. Given Metagenomi's stronger consensus rating and higher probable upside, research analysts plainly believe Metagenomi is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

75.3% of Moderna shares are held by institutional investors. 12.5% of Metagenomi shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Moderna beats Metagenomi on 10 of the 17 factors compared between the two stocks.

How does Metagenomi compare to PepGen?

Metagenomi (NASDAQ:MGX) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

In the previous week, Metagenomi had 2 more articles in the media than PepGen. MarketBeat recorded 2 mentions for Metagenomi and 0 mentions for PepGen. Metagenomi's average media sentiment score of 0.00 equaled PepGen'saverage media sentiment score.

Company	Overall Sentiment
Metagenomi	Neutral
PepGen	Neutral

Metagenomi has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, PepGen has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market.

PepGen has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. PepGen's return on equity of -51.01% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
PepGen	N/A	-51.01%	-43.49%

Metagenomi presently has a consensus target price of $6.00, suggesting a potential upside of 488.24%. PepGen has a consensus target price of $11.40, suggesting a potential upside of 400.00%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than PepGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Metagenomi has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.53	-$87.87M	-$2.49	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

58.0% of PepGen shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Metagenomi beats PepGen on 8 of the 15 factors compared between the two stocks.

How does Metagenomi compare to Precision BioSciences?

Metagenomi (NASDAQ:MGX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Precision BioSciences had 5 more articles in the media than Metagenomi. MarketBeat recorded 7 mentions for Precision BioSciences and 2 mentions for Metagenomi. Precision BioSciences' average media sentiment score of 0.85 beat Metagenomi's score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precision BioSciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precision BioSciences has a net margin of -96.73% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
Precision BioSciences	-96.73%	-72.52%	-32.25%

Metagenomi presently has a consensus target price of $6.00, suggesting a potential upside of 488.24%. Precision BioSciences has a consensus target price of $32.25, suggesting a potential upside of 411.09%. Given Metagenomi's stronger consensus rating and higher possible upside, equities analysts clearly believe Metagenomi is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

38.0% of Precision BioSciences shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Precision BioSciences has higher revenue and earnings than Metagenomi. Precision BioSciences is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.53	-$87.87M	-$2.49	N/A
Precision BioSciences	$34.26M	5.08	-$45.72M	-$2.80	N/A

Metagenomi has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Summary

Precision BioSciences beats Metagenomi on 10 of the 17 factors compared between the two stocks.

How does Metagenomi compare to Acumen Pharmaceuticals?

Metagenomi (NASDAQ:MGX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Metagenomi had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 2 mentions for Metagenomi and 0 mentions for Acumen Pharmaceuticals. Metagenomi's average media sentiment score of 0.00 equaled Acumen Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Metagenomi	Neutral
Acumen Pharmaceuticals	Neutral

Acumen Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

Metagenomi currently has a consensus target price of $6.00, suggesting a potential upside of 488.24%. Acumen Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 243.14%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts clearly believe Metagenomi is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Metagenomi has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 12.5% of Metagenomi shares are held by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Metagenomi has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.53	-$87.87M	-$2.49	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

Summary

Metagenomi beats Acumen Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Metagenomi compare to Lucid Diagnostics?

Metagenomi (NASDAQ:MGX) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Metagenomi has a net margin of -384.61% compared to Lucid Diagnostics' net margin of -959.76%. Lucid Diagnostics' return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
Lucid Diagnostics	-959.76%	N/A	-119.57%

Lucid Diagnostics has lower revenue, but higher earnings than Metagenomi. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.53	-$87.87M	-$2.49	N/A
Lucid Diagnostics	$4.71M	27.07	-$58.01M	-$0.47	N/A

Metagenomi has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Metagenomi presently has a consensus target price of $6.00, suggesting a potential upside of 488.24%. Lucid Diagnostics has a consensus target price of $4.19, suggesting a potential upside of 567.54%. Given Lucid Diagnostics' higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Metagenomi had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 2 mentions for Metagenomi and 1 mentions for Lucid Diagnostics. Metagenomi's average media sentiment score of 0.00 equaled Lucid Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

74.0% of Lucid Diagnostics shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metagenomi and Lucid Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGX vs. The Competition

Export

Metric	Metagenomi	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$38.53M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-0.41	13.00	274.71	26.04
Price / Sales	1.53	1,288.64	656.46	105.13
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	0.24	16.57	10.93	6.31
Net Income	-$87.87M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-11.30%	-2.97%	-2.00%	-1.66%
1 Month Performance	-12.82%	-10.82%	-6.19%	-4.68%
1 Year Performance	-61.51%	19.00%	8.03%	1.57%

Metagenomi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGX Metagenomi	3.4226 of 5 stars	$1.02 -7.7%	$6.00 +488.2%	-61.5%	$38.53M	$25.21M	N/A	113	News Coverage
MRNA Moderna	1.9397 of 5 stars	$199.41 +1.1%	$76.72 -61.5%	+566.9%	$79.39B	$1.94B	N/A	4,700	Trending News Analyst Downgrade
PEPG PepGen	1.3318 of 5 stars	$2.47 -4.8%	$11.40 +362.5%	-55.6%	$170.73M	N/A	N/A	57	Positive News
DTIL Precision BioSciences	3.7908 of 5 stars	$6.10 -2.2%	$32.25 +428.7%	+16.0%	$168.36M	$34.26M	N/A	67
ABOS Acumen Pharmaceuticals	2.5746 of 5 stars	$2.33 +1.1%	$7.00 +201.1%	+17.9%	$168.07M	N/A	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Metagenomi (MGX) Competitors

MGX vs. MRNA, PEPG, DTIL, ABOS, and LUCD

How does Metagenomi compare to Moderna?

Summary

How does Metagenomi compare to PepGen?

Summary

How does Metagenomi compare to Precision BioSciences?

Summary

How does Metagenomi compare to Acumen Pharmaceuticals?

Summary

How does Metagenomi compare to Lucid Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Metagenomi (MGX) Competitors

MGX vs. MRNA, PEPG, DTIL, ABOS, and LUCD

How does Metagenomi compare to Moderna?

Which has more risk & volatility, MGX or MRNA?

Does the media prefer MGX or MRNA?

Which has higher earnings and valuation, MGX or MRNA?

Is MGX or MRNA more profitable?

Do analysts rate MGX or MRNA?

Do insiders & institutionals hold more shares of MGX or MRNA?

Summary

How does Metagenomi compare to PepGen?

Does the media favor MGX or PEPG?

Which has more volatility & risk, MGX or PEPG?

Is MGX or PEPG more profitable?

Do analysts recommend MGX or PEPG?

Which has higher earnings & valuation, MGX or PEPG?

Do insiders and institutionals have more ownership in MGX or PEPG?

Summary

How does Metagenomi compare to Precision BioSciences?

Does the media prefer MGX or DTIL?

Is MGX or DTIL more profitable?

Do analysts recommend MGX or DTIL?

Do institutionals and insiders hold more shares of MGX or DTIL?

Which has higher valuation and earnings, MGX or DTIL?

Which has more volatility and risk, MGX or DTIL?

Summary

How does Metagenomi compare to Acumen Pharmaceuticals?

Does the media refer more to MGX or ABOS?

Is MGX or ABOS more profitable?

Do analysts rate MGX or ABOS?

Which has more risk & volatility, MGX or ABOS?

Do insiders & institutionals hold more shares of MGX or ABOS?

Which has preferable valuation and earnings, MGX or ABOS?

Summary

How does Metagenomi compare to Lucid Diagnostics?

Is MGX or LUCD more profitable?

Which has preferable valuation and earnings, MGX or LUCD?

Which has more volatility & risk, MGX or LUCD?

Do analysts prefer MGX or LUCD?

Does the media favor MGX or LUCD?

Do institutionals & insiders hold more shares of MGX or LUCD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools